FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009921622> ?p ?o ?g. }

• W2009921622 endingPage "151" @default.
• W2009921622 startingPage "146" @default.
• W2009921622 abstract "AimsTo investigate the presumed influence of hormone replacement therapy (HRT) on the progression of and death due to breast cancer.MethodsIn order to make a detailed analysis, we selected a group of 21 patients with the diagnosis of invasive breast cancer who had HRT after primary surgical treatment. Each patient from the selected group was compared with two patients from the control group with the diagnosis of invasive breast cancer who did not have HRT after primary surgical treatment. The control cases were matched to selected HRT patients with regard to age at time of the diagnosis, year of diagnosis, diameter of the tumour, metastatic spread in the axillary lymph nodes, and disease-free interval until applying HRT. The same criteria were applied in all analyses. The data were analysed by odds ratio (OR) calculation with a confidence interval of 95%, taking into account residual malignancy and death due to breast cancer in both groups (including carcinoma in the contralateral breast).ResultsHRT was applied in 21 patients treated for breast cancer. In 33% of them, radical mastectomy revealed metastases in the axillary lymph nodes. Hormone receptors could not be found in 57% of patients. In the majority of patients the tumour measured 17.6 mm in diameter. HRT was started on average 62 months (range 1–180 months) after diagnosis, and lasted an average of 28 months (range 3–72 months). All 21 patients used oestradiol as HRT, i.e. a non-conjugated oestrogen. Combined hormonal therapy (oestrogens + progestagens) was given to 95% of patients with median age of 47 years (range 41–59 years) at the beginning of HRT. Relapse was observed in four patients (19%) of the HRT group; of these, one had a carcinoma of the contralateral breast. In the control group, relapse was observed in five patients (11%); one of these five patients had a carcinoma of the contralateral breast. In the HRT group, there were no deaths among the patients with confirmed relapse, while one patient died in the control group. The estimated risk (OR=1.74, 95% CI 0.34–8.88) of relapse of breast cancer was calculated by comparing data from HRT users, who had received HRT for 28 months (range 3–72 months) on average, with data from the control group. The estimated risk of breast cancer relapse in HRT users who had been receiving HRT for less than 24 months was 0.65 (OR=0.65, 95% CI 0.02–7.85).ConclusionDespite the inherent limitations of retrospective data and the need for prospective randomized trials to assess the possible influence of HRT on progression after breast cancer treatment, the present observations suggest that HRT treatment for less than 24 months does not appear to have a pronounced adverse effect on cancer outcome. Nevertheless, until appropriate clinical trials determine that HRT is safe, caution is needed." @default.
• W2009921622 created "2016-06-24" @default.
• W2009921622 creator A5018774737 @default.
• W2009921622 creator A5026989609 @default.
• W2009921622 date "1999-04-01" @default.
• W2009921622 modified "2023-09-25" @default.
• W2009921622 title "A case-control study of hormone replacement therapy after primary surgical breast cancer treatment" @default.
• W2009921622 cites W1554522360 @default.
• W2009921622 cites W1849654724 @default.
• W2009921622 cites W1967719934 @default.
• W2009921622 cites W1976912643 @default.
• W2009921622 cites W1978787253 @default.
• W2009921622 cites W1979071811 @default.
• W2009921622 cites W1994185207 @default.
• W2009921622 cites W2001150352 @default.
• W2009921622 cites W2017880591 @default.
• W2009921622 cites W2020107395 @default.
• W2009921622 cites W2024808356 @default.
• W2009921622 cites W2028109121 @default.
• W2009921622 cites W2037982368 @default.
• W2009921622 cites W2045477011 @default.
• W2009921622 cites W2052218780 @default.
• W2009921622 cites W2054318265 @default.
• W2009921622 cites W2067334359 @default.
• W2009921622 cites W2079736780 @default.
• W2009921622 cites W2097128357 @default.
• W2009921622 cites W2103419792 @default.
• W2009921622 cites W2120955256 @default.
• W2009921622 cites W2289353246 @default.
• W2009921622 cites W2314604683 @default.
• W2009921622 cites W2321712742 @default.
• W2009921622 cites W2399189465 @default.
• W2009921622 cites W2406064103 @default.
• W2009921622 cites W2460674921 @default.
• W2009921622 cites W2469416225 @default.
• W2009921622 cites W2607238143 @default.
• W2009921622 cites W3164131268 @default.
• W2009921622 doi "https://doi.org/10.1053/ejso.1998.0617" @default.
• W2009921622 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10218456" @default.
• W2009921622 hasPublicationYear "1999" @default.
• W2009921622 type Work @default.
• W2009921622 sameAs 2009921622 @default.
• W2009921622 citedByCount "54" @default.
• W2009921622 countsByYear W20099216222012 @default.
• W2009921622 countsByYear W20099216222015 @default.
• W2009921622 countsByYear W20099216222016 @default.
• W2009921622 countsByYear W20099216222017 @default.
• W2009921622 countsByYear W20099216222018 @default.
• W2009921622 countsByYear W20099216222019 @default.
• W2009921622 countsByYear W20099216222021 @default.
• W2009921622 countsByYear W20099216222022 @default.
• W2009921622 crossrefType "journal-article" @default.
• W2009921622 hasAuthorship W2009921622A5018774737 @default.
• W2009921622 hasAuthorship W2009921622A5026989609 @default.
• W2009921622 hasConcept C121608353 @default.
• W2009921622 hasConcept C126322002 @default.
• W2009921622 hasConcept C141071460 @default.
• W2009921622 hasConcept C142724271 @default.
• W2009921622 hasConcept C143998085 @default.
• W2009921622 hasConcept C156957248 @default.
• W2009921622 hasConcept C2777649267 @default.
• W2009921622 hasConcept C2777757722 @default.
• W2009921622 hasConcept C2778311097 @default.
• W2009921622 hasConcept C2779279991 @default.
• W2009921622 hasConcept C2779399171 @default.
• W2009921622 hasConcept C2779720271 @default.
• W2009921622 hasConcept C2780159708 @default.
• W2009921622 hasConcept C2780275930 @default.
• W2009921622 hasConcept C29456083 @default.
• W2009921622 hasConcept C530470458 @default.
• W2009921622 hasConcept C71924100 @default.
• W2009921622 hasConceptScore W2009921622C121608353 @default.
• W2009921622 hasConceptScore W2009921622C126322002 @default.
• W2009921622 hasConceptScore W2009921622C141071460 @default.
• W2009921622 hasConceptScore W2009921622C142724271 @default.
• W2009921622 hasConceptScore W2009921622C143998085 @default.
• W2009921622 hasConceptScore W2009921622C156957248 @default.
• W2009921622 hasConceptScore W2009921622C2777649267 @default.
• W2009921622 hasConceptScore W2009921622C2777757722 @default.
• W2009921622 hasConceptScore W2009921622C2778311097 @default.
• W2009921622 hasConceptScore W2009921622C2779279991 @default.
• W2009921622 hasConceptScore W2009921622C2779399171 @default.
• W2009921622 hasConceptScore W2009921622C2779720271 @default.
• W2009921622 hasConceptScore W2009921622C2780159708 @default.
• W2009921622 hasConceptScore W2009921622C2780275930 @default.
• W2009921622 hasConceptScore W2009921622C29456083 @default.
• W2009921622 hasConceptScore W2009921622C530470458 @default.
• W2009921622 hasConceptScore W2009921622C71924100 @default.
• W2009921622 hasIssue "2" @default.
• W2009921622 hasLocation W20099216221 @default.
• W2009921622 hasLocation W20099216222 @default.
• W2009921622 hasOpenAccess W2009921622 @default.
• W2009921622 hasPrimaryLocation W20099216221 @default.
• W2009921622 hasRelatedWork W1845974318 @default.
• W2009921622 hasRelatedWork W1991544405 @default.
• W2009921622 hasRelatedWork W2034917757 @default.
• W2009921622 hasRelatedWork W2106576262 @default.
• W2009921622 hasRelatedWork W2109438123 @default.

• next